CD1A/B Rabbit Polyclonal Antibody
To Order Contact Us Below:
CD1A/B Polyclonal Antibody |
ES8784-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against CD1A/B from Human. This antibody is tested and validated for IHC, WB, ELISA |
Anti-CD1A/B antibody |
STJ98989 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Rabbit polyclonal to CD1A/B. |
CD1A Rabbit pAb |
A5722-100ul |
Abclonal |
100 ul |
EUR 369.6 |
CD1A Rabbit pAb |
A5722-200ul |
Abclonal |
200 ul |
EUR 550.8 |
CD1A Rabbit pAb |
A5722-20ul |
Abclonal |
20 ul |
EUR 219.6 |
CD1A Rabbit pAb |
A5722-50ul |
Abclonal |
50 ul |
EUR 267.6 |
CD1A antibody |
70R-16257 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal CD1A antibody |
CD1a Antibody |
49610-100ul |
SAB |
100ul |
EUR 399.6 |
CD1a Antibody |
49610-50ul |
SAB |
50ul |
EUR 286.8 |
CD1A Antibody |
32993-100ul |
SAB |
100ul |
EUR 302.4 |
CD1a antibody |
10R-6325 |
Fitzgerald |
100 ug |
EUR 249.6 |
Description: Mouse monoclonal CD1a antibody |
CD1A antibody |
10R-7787 |
Fitzgerald |
500 ug |
EUR 678 |
Description: Mouse monoclonal CD1A antibody |
CD1A antibody |
10R-10717 |
Fitzgerald |
100 ug |
EUR 418.8 |
Description: Mouse monoclonal CD1A antibody |
CD1A antibody |
10R-10739 |
Fitzgerald |
100 ug |
EUR 418.8 |
Description: Mouse monoclonal CD1A antibody |
CD1A Antibody |
1-CSB-PA789186 |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000 |
CD1A Antibody |
1-CSB-PA004889ESR1HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
CD1A Antibody |
1-CSB-PA004889ESR2HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200 |
CD1A Antibody |
1-CSB-PA004889GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD1A. Recognizes CD1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF |
CD1a Antibody |
V8193-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V8193-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V8193SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2948-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2948-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2948SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2949-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt] |
CD1a Antibody |
V2949-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt] |
CD1a Antibody |
V2949SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1a is an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells. [UniProt] |
CD1a Antibody |
V3253-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3253-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3253SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3541-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3541-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3541IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V3541SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7012-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7012-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7012SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7231-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin. |
CD1a Antibody |
V7231-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin. |
CD1a Antibody |
V7231IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin. |
CD1a Antibody |
V7231SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein expressed in association with Beta-2 microglobulin. |
CD1a Antibody |
V7376-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7376-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7376IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V7376SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2025-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2025-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2025IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2025SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict Tcell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since it is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. CD1a antibody is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2026-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2026-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2026IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V2026SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V4058-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V4058-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody |
V4058SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
Polyclonal CD1A antibody - C-terminal region |
APR01536G |
Leading Biology |
0.05mg |
EUR 633.6 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD1A - C-terminal region. This antibody is tested and proven to work in the following applications: |
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx159382 |
Abbexa |
|
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx139080-01mg |
Abbexa |
0.1 mg |
EUR 444 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx141314 |
Abbexa |
-
EUR 444.00
-
EUR 727.20
-
EUR 360.00
|
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx146226-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx004375 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx111464 |
Abbexa |
|
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx010518-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx015794-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx027451-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx027451-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx200001-100ug |
Abbexa |
100 ug |
EUR 393.6 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx320639 |
Abbexa |
|
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx322311 |
Abbexa |
|
|
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx415367-01mg |
Abbexa |
0.1 mg |
EUR 543.6 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx415541-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx415548-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx231434-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
abx231435-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
T-cell Surface Glycoprotein CD1a (CD1A) Antibody |
20-abx211317 |
Abbexa |
|
|
|
CD1a antibody (FITC) |
61R-1030 |
Fitzgerald |
100 tests |
EUR 379.2 |
Description: Mouse monoclonal CD1a antibody (FITC) |
CD1a(O10) Antibody |
BNC040667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF405S conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC040667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF405S conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC041034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF405S conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC041034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF405S conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC050667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF405M conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC050667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF405M conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCAP0667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCAP0667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCAP1034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCAP1034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCB0667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), Biotin conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCB0667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), Biotin conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCB1034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), Biotin conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCB1034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), Biotin conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCP0667-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(O10), PerCP conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCP1034-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(66IIC7), PerCP conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCR0667-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(O10), RPE conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCR1034-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(66IIC7), RPE conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC940667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF594 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC940667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF594 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC941034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF594 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC941034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF594 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCA0667-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(O10), APC conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCA1034-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD1a(66IIC7), APC conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC810667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC810667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC811034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC811034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNUB0667-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD1a(O10), Concentration: 0.2mg/mL |
CD1a(O10) Antibody |
BNUB0667-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD1a(O10), Concentration: 0.2mg/mL |
CD1a(66IIC7) Antibody |
BNUB1034-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD1a(66IIC7), Concentration: 0.2mg/mL |
CD1a(66IIC7) Antibody |
BNUB1034-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD1a(66IIC7), Concentration: 0.2mg/mL |
CD1a(O10) Antibody |
BNCH0667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNCH0667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCH1034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNCH1034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC880667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF488A conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC880667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF488A conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC881034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF488A conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC881034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF488A conjugate, Concentration: 0.1mg/mL |
CD1a Conjugated Antibody |
C49610 |
SAB |
100ul |
EUR 476.4 |
CD1a(O10) Antibody |
BNC680667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF568 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC680667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF568 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC681034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF568 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC681034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF568 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC470667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF647 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC470667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF647 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC471034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF647 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC471034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF647 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC400667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF640R conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC400667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF640R conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC401034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF640R conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC401034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF640R conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC430667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC430667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC431034-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(66IIC7), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a(66IIC7) Antibody |
BNC431034-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(66IIC7), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC550667-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD1a(O10), CF555 conjugate, Concentration: 0.1mg/mL |
CD1a(O10) Antibody |
BNC550667-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD1a(O10), CF555 conjugate, Concentration: 0.1mg/mL |
CD1A/B Rabbit Polyclonal Antibody